Fungal diseases span superficial and mucosal infections as well as invasive disease, and the biology differs substantially among Candida, Aspergillus, Fusarium and other organisms. For antifungal developers, growth inhibition alone rarely explains whether a candidate will perform against biofilms, suppress virulence traits, reach the site of infection or remain tolerable at an effective exposure.
Microbiome-based antifungal approaches add another layer: activity from Lactobacillus strains, culture supernatants or microbial metabolites depends on species, strain and experimental conditions. Creative Biolabs helps research teams bring these observations into a connected preclinical plan, selecting informative assays and disease-relevant models before resources are committed to later studies. This approach supports both antifungal drug discovery and carefully controlled microbial antagonism research.